Marketed as Mounjaro®, Tirzepatide is an innovative dual GIP/GLP-1 receptor agonist that offers a unique approach to managing Type 2 Diabetes (T2D). FDA-approved in 2022, it provides impressive benefits in glycemic control and weight reduction, achieving superior outcomes versus traditional GLP-1 receptor agonists. Notably, the SURPASS-4 trial indicated a mortality reduction in T2D patients using Tirzepatide over insulin glargine, marking it as a robust therapy. Its tolerable side-effect profile and significant metabolic benefits place it at the forefront of T2D management, with potential applications in obesity.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about TIRZEROW by Crowx Labs, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
